ERBB2 and breast carcinoma: Disappointingly, only a few target agents such as tratuzumab and lapatinib [6] have been recommended for combination therapy with capecitabine for human epidermal growth factor receptor 2 (Her-2)–positive breast cancer to improve outcomes, and other drugs, including sunitinib [7] and bevacizumab [8], have failed to improve outcomes in Her-2–negative breast cancer.